EHA 2021 | ZGJAK002: jaktinib shows efficacy in myelofibrosis

Jie Jin, MD, PhD, Zhejiang Medical University, Hangzhou, China, discusses the results of a Phase II ZGJAK002 trial (NCT03886415) of jaktinib, a novel JAK inhibitor, for the treatment of patients with myelofibrosis. The aim of the trial was to investigate the efficacy and safety of jaktinib in patients with myelofibrosis. 104 patients were randomized to receive either a 100mg BID dose or a 200mg QD dose of oral jaktinib. At 24 weeks of follow-up, the study reported a spleen volume reduction from baseline over 35% in 51.9% of patients in the 100mg BID cohort, and in 30.8% of patients in the 200mg QD cohort. The median duration of response has not been reached for the 100mg BID cohort, and was 47.9 weeks for the 200mg QD cohort. Overall, the study concluded that jaktinib is generally well-tolerated and achieved a greater rate of spleen volume reduction when administered as a 100mg BID dose, compared to a 200mg QD dose. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.